Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

NCT05768880 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT05768880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 5, 2023
Completion date
December 31, 2043
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, diffuse midline glioma, recurrent cns tumor, adult, recurrent, cns tumor, childhood, refractory primary malignant central nervous system neoplasm